このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Philogen マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Dario Neri

最高経営責任者

€150.0k

報酬総額

CEO給与比率	n/a
CEO在任期間	28.8yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Dario Neri (61 yo)

28.8yrs

在職期間

€150,000

報酬

Prof. Dr. Dario Neri, PhD co-founded Philogen S.p.A in 1996 and serves as its CSO, President of The Scientific Advisory Board and Chief Executive Officer and Managing Director. Prof. Dr. Neri served as Sc...

取締役

名称	ポジション	在職期間	報酬	所有権
Duccio Neri	Co-Founder & Executive Chairman	no data	€300.00k	データなし
Dario Neri	Co-Founder	no data	€150.00k	データなし
Giovanni Neri	Co-Founder	no data	€90.00k	データなし
Roberto Ferraresi	Independent Director	5.4yrs	€32.00k	データなし
Sergio Gianfranco Luigi Dompé	Director	no data	€30.00k	0.025% € 197.0k
Leopoldo Zambeletti	Director	no data	€30.00k	データなし
Nathalie Francesca Dompé	Director	no data	€30.00k	データなし
Guido Guidi	Member of Scientific Advisory Board & Director	5.4yrs	€32.00k	データなし
Marta Bavasso	Lead Independent Director	no data	€30.00k	データなし
Wolfgang Berdel	Member of Scientific Advisory Board	no data	データなし	データなし
Cornelia Winter	Member of Scientific Advisory Board	no data	データなし	データなし
Maria Calloni	Director	2.8yrs	€32.00k	データなし

5.4yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 78Qの取締役会は経験豊富であると考えられます ( 5.2年の平均在任期間)。

Philogen マネジメント

マネジメント基準チェック /34

主要情報

経営陣の近況

Less than half of directors are independent

Director recently bought €179k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Recent updates

First half 2024 earnings released

Less than half of directors are independent

Director recently bought €179k worth of stock

Full year 2023 earnings released

Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma

Philogen S.p.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities

New major risk - Revenue and earnings growth

Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma

First half 2023 earnings released: EPS: €0.19 (vs €0.049 in 1H 2022)

Philogen S.p.A. (BIT:PHIL) commences an Equity Buyback Plan for 500,000 shares, representing 1.23% of its issued share capital, under the authorization approved on April 28, 2023.

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.21 loss in 1H 2021)

Philogen S.p.A. Announces Enrolment of 214 Patients in the Nidlegy Phase III European Clinical Trial for the Treatment of Locally Advanced Melanoma

Less than half of directors are independent

Full year 2021 earnings released

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Director recently bought €4.7m worth of stock

Director recently bought €4.4m worth of stock

Philogen S.p.A. Announces R&D Program Update

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

Philogen マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Less than half of directors are independent

Director recently bought €179k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Recent updates

First half 2024 earnings released

Less than half of directors are independent

Director recently bought €179k worth of stock

Full year 2023 earnings released

Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma

Philogen S.p.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities

New major risk - Revenue and earnings growth

Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma

First half 2023 earnings released: EPS: €0.19 (vs €0.049 in 1H 2022)

Philogen S.p.A. (BIT:PHIL) commences an Equity Buyback Plan for 500,000 shares, representing 1.23% of its issued share capital, under the authorization approved on April 28, 2023.

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.21 loss in 1H 2021)

Philogen S.p.A. Announces Enrolment of 214 Patients in the Nidlegy Phase III European Clinical Trial for the Treatment of Locally Advanced Melanoma

Less than half of directors are independent

Full year 2021 earnings released

Director recently bought €377k worth of stock

Director recently bought €76k worth of stock

Director recently bought €4.7m worth of stock

Director recently bought €4.4m worth of stock

Philogen S.p.A. Announces R&D Program Update

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34